Current Allergy and Asthma Reports
Current Allergy and Asthma Reports (abbreviated as ''Curr. Allergy Asthma Rep.') is a peer-reviewed review journal in allergy and asthma published by Springer. Founded in 2001, it is now edited by Mariana C. Castells of Brigham and Women's Hospital, with a 2025 impact factor of 6.3.Current Allergy and Asthma Reports（常用缩写 Curr. Allergy Asthma Rep.）是施普林格（Springer）出版的过敏与哮喘领域同行评审综述期刊，创刊于 2001 年，现由布赖顿妇女医院（Brigham and Women's Hospital）的 Mariana C. Castells 担任主编，2025 年影响因子为 6.3。[1]
Scope
The journal is dedicated to in-depth review articles contributed by international experts, presenting clear, insightful and balanced reviews that emphasize recently published papers of major importance in order to elucidate current and emerging approaches to the diagnosis, treatment, management and prevention of allergy and asthma.该刊的定位是刊载国际知名专家撰写的深度综述，通过清晰、中肯、平衡的综述文章着重梳理近期发表的重要文献，阐明过敏与哮喘在诊断、治疗、管理与预防方面的现行方法与新近进展。
- Basic and applied science: fundamental mechanisms and their clinical application in allergy and asthma, including advances in immunologic and diagnostic testing methodology.基础与应用科学： 刊发过敏与哮喘领域的基础机制及其临床应用，涵盖免疫学与诊断试验方法学的进展。
- The allergic disease spectrum: progress in diagnosis and treatment across environmental allergy, occupational allergy, allergic skin disease, asthma and immunotherapy.过敏性疾病谱： 覆盖环境相关过敏、职业性过敏、过敏性皮肤病、哮喘与免疫治疗等常见与难治性疾病的诊治进展。
- Special presentations and emergencies: anaphylaxis and drug allergy, immune deficiency and dysregulation, and systemic mastocytosis, conditions that demand rapid recognition or long-term follow-up.特殊类型与急重症： 关注过敏性反应与药物过敏、免疫缺陷与免疫失调、全身性肥大细胞病等需要紧急识别或长期随访的病症。
- Emerging technology: new approaches drawn from telemedicine, wearable devices and artificial intelligence as applied to allergy and asthma care.新技术应用： 主动吸纳远程医疗、可穿戴设备与人工智能在过敏与哮喘管理中的新方法。
The journal appears under a hybrid open-access model, giving subscribers unrestricted access while others may pay to publish open access. Manuscripts are submitted through the publisher's online submission system and, once accepted after peer review, are grouped by section.出版模型为混合开放获取，订阅机构可免费阅读全文，非订阅机构可选择付费方式将文章开放获取；稿件在出版方的在线投稿系统中提交，录用后经同行评审并按栏目归类编排。
History
- 2001: the journal was founded in Philadelphia by the local publisher Current Science, with the allergy specialist David Peden of the University of North Carolina at Chapel Hill School of Medicine as its first Editor-in-Chief. From the outset it was conceived as a review journal of high standing for the allergy and asthma field.2001年： 期刊在美国费城创刊，由当地出版商 Current Science 承办，首任主编为北卡罗来纳大学教堂山分校医学院的过敏专科医师 David Peden，创办之初即定位为过敏与哮喘领域的高质量综述专刊。
- The 2000s: as the publishing business was consolidated, the journal moved into the Springer medical journal portfolio, keeping its existing identifiers and readership.2000年代： 随着出版方业务整合，期刊转入 Springer 的医学期刊序列，沿用原有的刊号与读者基础继续出版。
- The 2010s: the fixed bimonthly schedule gave way to online-first publication, and print distribution contracted until it stopped altogether.2010年代： 出版节奏由固定双月刊逐步转为在线优先发表，纸本发行逐渐收缩直至停止。
- The 2020s: the journal is now online only. The former print ISSN 1529-7322 has been ceased, while the electronic ISSN 1534-6315 remains valid.2020年代： 已成为纯在线期刊，原纸本国际标准连续出版物号 1529-7322 停用，电子版号 1534-6315 继续有效。
- Impact: the impact factor stood at 2.765 in 2014, recovered to 3.2 in 2023 and reached 6.3 in 2025, with a five-year impact factor of 6.5. The journal is indexed in the Science Citation Index Expanded, MEDLINE and EMBASE.影响力： 2014 年影响因子为 2.765，2023 年回升至 3.2，2025 年达到 6.3，五年影响因子为 6.5，被科学引文索引扩展版、医学文献数据库与 Excerpta Medica 数据库收录。
- Change of editor: editorial work was first led by David Peden and has since passed to Mariana C. Castells, who directs two specialist centres for drug hypersensitivity and mastocytosis.主编更替： 编辑工作最初由 David Peden 主持，现已交由 Mariana C. Castells，接任者同时担任药物超敏反应与肥大细胞病两个专门中心的负责人。
Editors
The journal is led by a single Editor-in-Chief and supported by eleven section editors and a board spread across many countries, with peer review and acceptance handled jointly by the Editor-in-Chief and the section editors.该刊设主编一人，另配十一名栏目编辑与一支横跨多国的编委，稿件的评审与录用由主编和栏目编辑分工完成。
- Editor-in-Chief: Mariana C. Castells, MD, PhD, directs the Drug Hypersensitivity and Desensitization Center and the Mastocytosis Center at Brigham and Women's Hospital and is Professor of Medicine at Harvard Medical School, with clinical and research interests in drug allergy and mastocytosis.主编： Mariana C. Castells 为医学博士与哲学博士，任布赖顿妇女医院药物超敏反应与脱敏中心及肥大细胞病中心主任，并任哈佛医学院内科教授，其临床与研究重心落在药物过敏与肥大细胞病。
- Sections: the current section editors cover basic and applied science, allergies and the environment, occupational allergies, autoimmunity, anaphylaxis and drug allergy, immune deficiency and dysregulation, systemic mastocytosis, telemedicine and artificial intelligence, allergic skin diseases, asthma, and immunotherapy and immunomodulators, giving eleven areas in all.栏目设置： 现任栏目编辑分别负责基础与应用科学、环境相关过敏、职业性过敏、自身免疫、过敏性反应与药物过敏、免疫缺陷与免疫失调、全身性肥大细胞病、远程医疗技术与人工智能、过敏性皮肤病、哮喘以及免疫治疗与免疫调节剂等十一个方向。
- Board composition: board members come from Spain, Germany, the United States, Canada, Singapore, Argentina, Australia, Brazil, the United Arab Emirates, Japan, the Philippines and South Africa, several of them holding presidencies in international societies.编委构成： 编委成员来自西班牙、德国、美国、加拿大、新加坡、阿根廷、澳大利亚、巴西、阿联酋、日本、菲律宾与南非等地，其中多人兼任国际学会的会长或主席职务。
- Topical collections: standing collections on hot topics in allergy and asthma, immunologic and diagnostic tests in allergy, and mast cell activation disorders group multiple reviews around a single theme. Manuscripts are submitted through the publisher's online submission system.专题专辑： 常年开设过敏与哮喘热点、免疫与诊断试验、肥大细胞活化障碍等专题专辑，把同一主题下的多篇综述编为一组发表，作者经出版方在线投稿系统提交稿件。[2]